Latest news with #Neutrogena®
Hamilton Spectator
20-05-2025
- Health
- Hamilton Spectator
REPEAT: Rocket Doctor Partners with Melanoma Canada to Expand Access to Follow-Up Care for At-Risk Patients
New collaboration will connect patients flagged during mobile skin cancer screenings with Rocket Doctor physicians across Ontario, Alberta, and British Columbia ●Rocket Doctor has partnered with Melanoma Canada to provide timely follow-up care for patients identified as at-risk during mobile skin cancer screenings. ●Patients without a family doctor will be directly referred to physicians on Rocket Doctor through a streamlined digital intake process. ●The Mole Mobile campaign travels across Alberta, British Columbia, Ontario, and Quebec, providing free screenings in both remote and urban communities. ● Skin cancer is the most common cancer in Canada, with 1 in 3 cancer diagnoses being skin-related — more than breast, prostate, lung, and colon cancers combined. ● 22 Canadians are diagnosed with melanoma every day, and 3 Canadians die daily from this serious form of skin cancer. ●The partnership is expected to increase patient visits on Rocket Doctor's platform, improving access to care and continuity for at-risk individuals. Toronto, ON, May 20, 2025 (GLOBE NEWSWIRE) — AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) ('Treatment') is proud to announce that its virtual care subsidiary, Rocket Doctor Inc., has partnered with Melanoma Canada to help bridge the care gap for individuals identified as at-risk for melanoma and other skin cancers during mobile screening events across the country. Melanoma Canada's Mole Mobile units, Canada's first mobile skin cancer screening clinics, presented by Neutrogena®, a Kenvue brand travel across Alberta, British Columbia, Ontario, and Quebec, offering free skin checks from certified dermatologists in both remote and urban communities. Through this partnership, Rocket Doctor will provide patients who do not have a family physician with timely access to follow-up appointments via its virtual care platform. 'Too many Canadians are going without the care they need simply because they don't have a family doctor,' said Dr. William Cherniak, Founder and CEO of Rocket Doctor. 'By partnering with Melanoma Canada, we're making it easier for patients identified during these critical screenings to get connected to a physician quickly, ensuring no one falls through the cracks.' Dermatologists working in the Mole Mobile units will complete an on-site risk assessment and referral form for patients who require follow-up. These forms can then be uploaded directly to Rocket Doctor's intake system, enabling efficient, streamlined review and timely access to appropriate care. The need for follow-up care has never been more urgent. Skin cancer is the most commonly diagnosed cancer in Canada, more prevalent than breast, prostate, lung, and colon cancers combined. One in every three cancers diagnosed in Canada is a skin cancer, and the incidence of melanoma, the deadliest form, continues to rise. Every day, 22 Canadians are diagnosed with melanoma, and 3 die from it. 'With one in three cancers diagnosed in Canada being skin cancer, access to timely follow-up care is crucial,' said Falyn Katz, CEO of Melanoma Canada. 'Our partnership with Rocket Doctor ensures that individuals flagged during our screenings, many of whom don't have a family doctor, can seamlessly transition from screening to care. It's a powerful step forward in improving outcomes for patients who might otherwise be left waiting.' The initiative is expected to increase patient traffic across Rocket Doctor's platform during Mole Mobile's national tour, while reinforcing Rocket Doctor's mission to improve equitable access to physician-led care. As part of the collaboration, Rocket Doctor's logo will also appear on Mole Mobile vans and campaign materials, which collectively generate millions of impressions throughout the tour. The term of this Agreement is 12 months commencing February 3, 2025, and will automatically renew for successive 12-month periods unless either party provides at least 30 days' written notice of termination prior to the renewal date. Initial events will kick off in Toronto and Edmonton this spring, with additional stops planned through October 2025. About Rocket Doctor Inc. Rocket Doctor is a technology-driven digital health platform and marketplace that empowers doctors to build and manage their own virtual or hybrid practices. Its proprietary software and AI-powered tools enable providers to deliver high-quality care remotely, with a focus on reaching underserved and remote communities across North America. By removing barriers to care and restoring physician autonomy, Rocket Doctor is redefining what modern healthcare looks like. Visit or contact media@ . About Melanoma Canada Melanoma Canada is a national organization dedicated to raising awareness, advancing prevention, and supporting patients affected by melanoma and skin cancer. Through programs like the Mole Mobile, Canada's first mobile skin cancer screening initiative, Melanoma Canada brings early detection, education, and hope to communities across the country. In partnership with Canadian dermatologists, the Mole Mobile has screened thousands of individuals and identified hundreds of potential skin cancers. Learn more at . About AI Inc. AI is a company utilizing AI (artificial intelligence) and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, AI has built a comprehensive, personalized healthcare AI engine — the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals as well as providing recommended tests (physical and lab), imaging and billing codes. The GLM helps healthcare professionals (doctors, nurses or pharmacists) reduce their administrative burden; creates more time for needed face-to-face patient appointments; and enables greater consistency in quality of patient support. AI's GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities. Learn more at or contact info@ . FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO Email: ehamza@ Media inquiries: media@ Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955 Cautionary Statement This news release contains forward-looking statements that are based on AI's expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Hamilton Spectator
20-05-2025
- Health
- Hamilton Spectator
Rocket Doctor Partners with Melanoma Canada to Expand Access to Follow-Up Care for At-Risk Patients
New collaboration will connect patients flagged during mobile skin cancer screenings with Rocket Doctor physicians across Ontario, Alberta, and British Columbia ●Rocket Doctor has partnered with Melanoma Canada to provide timely follow-up care for patients identified as at-risk during mobile skin cancer screenings. ●Patients without a family doctor will be directly referred to physicians on Rocket Doctor through a streamlined digital intake process. ●The Mole Mobile campaign travels across Alberta, British Columbia, Ontario, and Quebec, providing free screenings in both remote and urban communities. ● Skin cancer is the most common cancer in Canada, with 1 in 3 cancer diagnoses being skin-related — more than breast, prostate, lung, and colon cancers combined. ● 22 Canadians are diagnosed with melanoma every day, and 3 Canadians die daily from this serious form of skin cancer. ●The partnership is expected to increase patient visits on Rocket Doctor's platform, improving access to care and continuity for at-risk individuals. Toronto, ON, May 20, 2025 (GLOBE NEWSWIRE) — AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) ('Treatment') is proud to announce that its virtual care subsidiary, Rocket Doctor Inc., has partnered with Melanoma Canada to help bridge the care gap for individuals identified as at-risk for melanoma and other skin cancers during mobile screening events across the country. Melanoma Canada's Mole Mobile units, Canada's first mobile skin cancer screening clinics, presented by Neutrogena®, a Kenvue brand travel across Alberta, British Columbia, Ontario, and Quebec, offering free skin checks from certified dermatologists in both remote and urban communities. Through this partnership, Rocket Doctor will provide patients who do not have a family physician with timely access to follow-up appointments via its virtual care platform. 'Too many Canadians are going without the care they need simply because they don't have a family doctor,' said Dr. William Cherniak, Founder and CEO of Rocket Doctor. 'By partnering with Melanoma Canada, we're making it easier for patients identified during these critical screenings to get connected to a physician quickly, ensuring no one falls through the cracks.' Dermatologists working in the Mole Mobile units will complete an on-site risk assessment and referral form for patients who require follow-up. These forms can then be uploaded directly to Rocket Doctor's intake system, enabling efficient, streamlined review and timely access to appropriate care. The need for follow-up care has never been more urgent. Skin cancer is the most commonly diagnosed cancer in Canada, more prevalent than breast, prostate, lung, and colon cancers combined. One in every three cancers diagnosed in Canada is a skin cancer, and the incidence of melanoma, the deadliest form, continues to rise. Every day, 22 Canadians are diagnosed with melanoma, and 3 die from it. 'With one in three cancers diagnosed in Canada being skin cancer, access to timely follow-up care is crucial,' said Falyn Katz, CEO of Melanoma Canada. 'Our partnership with Rocket Doctor ensures that individuals flagged during our screenings, many of whom don't have a family doctor, can seamlessly transition from screening to care. It's a powerful step forward in improving outcomes for patients who might otherwise be left waiting.' The initiative is expected to increase patient traffic across Rocket Doctor's platform during Mole Mobile's national tour, while reinforcing Rocket Doctor's mission to improve equitable access to physician-led care. As part of the collaboration, Rocket Doctor's logo will also appear on Mole Mobile vans and campaign materials, which collectively generate millions of impressions throughout the tour. The term of this Agreement is 12 months commencing February 3, 2025, and will automatically renew for successive 12-month periods unless either party provides at least 30 days' written notice of termination prior to the renewal date. Initial events will kick off in Toronto and Edmonton this spring, with additional stops planned through October 2025. About Rocket Doctor Inc. Rocket Doctor is a technology-driven digital health platform and marketplace that empowers doctors to build and manage their own virtual or hybrid practices. Its proprietary software and AI-powered tools enable providers to deliver high-quality care remotely, with a focus on reaching underserved and remote communities across North America. By removing barriers to care and restoring physician autonomy, Rocket Doctor is redefining what modern healthcare looks like. Visit or contact media@ . About Melanoma Canada Melanoma Canada is a national organization dedicated to raising awareness, advancing prevention, and supporting patients affected by melanoma and skin cancer. Through programs like the Mole Mobile, Canada's first mobile skin cancer screening initiative, Melanoma Canada brings early detection, education, and hope to communities across the country. In partnership with Canadian dermatologists, the Mole Mobile has screened thousands of individuals and identified hundreds of potential skin cancers. Learn more at . About AI Inc. AI is a company utilizing AI (artificial intelligence) and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, AI has built a comprehensive, personalized healthcare AI engine — the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals as well as providing recommended tests (physical and lab), imaging and billing codes. The GLM helps healthcare professionals (doctors, nurses or pharmacists) reduce their administrative burden; creates more time for needed face-to-face patient appointments; and enables greater consistency in quality of patient support. AI's GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities. Learn more at or contact info@ . FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO Email: ehamza@ Media inquiries: media@ Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955 Cautionary Statement This news release contains forward-looking statements that are based on AI's expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Yahoo
04-02-2025
- Entertainment
- Yahoo
Neutrogena® Introduces Tate McRae as Global Brand Ambassador
On the Heels of its 10th Anniversary, the Brand's Iconic Hydro Boost Collection Is Revealing a Juicy, Fresh Take SKILLMAN, N.J., Feb. 4, 2025 /CNW/ -- Kenvue Inc. (NYSE: KVUE) announces global sensation Tate McRae as the newest face of Neutrogena®. This announcement marks the debut campaign under Neutrogena's bold new positioning, 'Beauty to a Science,' which exemplifies the brand's 90-year history of developing advanced clinical science while designing incredible product experiences. Neutrogena's new campaign highlights products from its award-winning Hydro Boost range, including the Water Gel. This commemorates Hydro Boost's 10th anniversary as one of the brand's top-selling facial moisturizers, which jumpstarted the hyaluronic acid ingredient category. On average, a jar of Neutrogena Hydro Boost Water Gel is sold every two seconds worldwide1. At just 21 years old, McRae has captivated audiences as a chart-topping artist and dancer. Now, as she prepares to release her third album, So Close to What, and hit the road for a world tour, the campaign shares her must-have secret to juicy skin: Neutrogena Hydro Boost. "I'm thrilled to partner with Neutrogena – a brand I've trusted since I was young. What I love about this campaign is how real it feels. We've all been there—those moments where your brain just won't stop spiraling, and the last thing you need is the overthinking messing up your skin," said McRae, Neutrogena® Global Brand Ambassador. "That's why I'm obsessed with Hydro Boost. It keeps my skin hydrated and is the perfect reminder that skincare doesn't have to be complicated to work." Neutrogena engages best-in-class scientists and partners with leading dermatologists to develop breakthrough solutions that both advance clinical efficacy and provide incredible product experience. In the upcoming campaign, McRae stars alongside Neutrogena® Global Innovation Partner, Dr. Muneeb Shah, to highlight how stress and overthinking can affect skin. "By featuring Tate and her infectious energy, alongside Dr. Shah, whose expertise helped to make him the most followed dermatologist on social media, we're bridging the gap between beauty and science, creating a powerful message for the next generation," said Andrew Stanleick, Kenvue's President of Skin Health & Beauty in North America, Europe, Middle East, and Africa. "With Neutrogena Hydro Boost, we're redefining hydration and showing how skincare can empower you to feel your best every day." As a Neutrogena® Global Ambassador, McRae will be featured in marketing initiatives across multiple platforms, including TV, social, digital, point of sale, and will also integrate the brand into her own future projects. The campaign emphasizes Hydro Boost's ability to enhance skincare routines with a weightless formula that magnifies the power of hyaluronic acid for juicy, deeply hydrated skin. About KenvueKenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that power in consumers' hands and earn a place in their hearts and homes. Learn more at About Neutrogena®For over 90 years, Neutrogena® has been developing breakthrough skincare solutions that both advance clinical efficacy and provide incredible product experience. From science-led innovation to accessible education, we are driven by a mission to democratize skin health & beauty. Our products address skin needs across ages, skin types and tones. Neutrogena® is a brand of Kenvue Brands LLC, a subsidiary of Kenvue Inc. About Tate McRae:Singer, songwriter, and dancer triple threat Tate McRae has garnered over 12.6 billion career streams and multiple #1 Top 40 hits. Her versatility as a performer has captivated audiences around the world. Whether she's delivering a powerful vocal performance or executing high-energy choreography, Tate brings a unique blend of artistry and authenticity to every stage. Her highly anticipated third album So Close To What is releasing February 21st. Cautions Concerning Forward-Looking Statements This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding Neutrogena's introduction of Tate McRae as Global Brand Ambassador. Forward-looking statements may be identified by the use of words such as "plans," "expects," "will," "anticipates," "estimates" and other words of similar meaning. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kenvue and its affiliates. A list and descriptions of risks, uncertainties and other factors can be found in Kenvue's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q and other filings, available at or on request from Kenvue. Kenvue and its affiliates undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or developments or otherwise. 1 *Based on global unit sales data for L52W ending Oct 2024 Media Contact: Jenni Évora Communications Lead, Neutrogenajevora@ View original content to download multimedia: SOURCE Kenvue Inc. View original content to download multimedia: Sign in to access your portfolio
